欧州連合 - オランダ語 - EMA (European Medicines Agency)

janssen-cilag international n.v. - daratumumab - multiple myeloma - monoclonal antibodies and antibody drug conjugates, antineoplastic agents - multiple myelomadarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. in combinatie met bortezomib, thalidomide en dexamethason voor de behandeling van volwassen patiënten met nieuw gediagnosticeerde multipel myeloom die in aanmerking komen voor een autologe stamceltransplantatie. in combinatie met lenalidomide en dexamethason, of bortezomib en dexamethason voor de behandeling van volwassen patiënten met multipel myeloom die minstens één eerdere therapie. in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5. als monotherapie voor de behandeling van volwassen patiënten met recidief en refractair multipel myeloom, van wie eerdere therapie opgenomen een proteasoom-remmer en een immunomodulerende agent en die blijk hebben gegeven van progressie van de ziekte op de laatste therapie. al amyloidosisdarzalex is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (al) amyloidosis.

欧州連合 - オランダ語 - EMA (European Medicines Agency)

kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastische middelen - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.

欧州連合 - オランダ語 - EMA (European Medicines Agency)

mylan ireland limited - sugammadex sodium - neuromusculaire blokkade - alle andere therapeutische producten - reversal of neuromuscular blockade induced by   rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

欧州連合 - オランダ語 - EMA (European Medicines Agency)

amgen europe bv - sotorasib - carcinoom, niet-kleincellige long - antineoplastische middelen - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

欧州連合 - オランダ語 - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - multiple myeloma - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

欧州連合 - オランダ語 - EMA (European Medicines Agency)

aop orphan pharmaceuticals gmbh - sugammadex sodium - neuromusculaire blokkade - alle andere therapeutische producten - omkering van neuromusculaire blokkade geïnduceerd door rocuronium of vecuronium. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

欧州連合 - オランダ語 - EMA (European Medicines Agency)

extrovis eu ltd. - sugammadex sodium - neuromusculaire blokkade - alle andere therapeutische producten - reversal of neuromuscular blockade induced by rocuronium or vecuronium in adults. for the paediatric population: sugammadex is only recommended for routine reversal of rocuronium induced blockade in children and adolescents aged 2 to 17 years.

欧州連合 - オランダ語 - EMA (European Medicines Agency)

glaxo group ltd. - fluticasonfuroaat - rhinitis, allergic, perennial; rhinitis, allergic, seasonal - neuspreparaten - volwassenen, adolescenten (12 jaar en ouder) en kinderen (6 - 11 jaar). alisade is geïndiceerd voor de behandeling van de symptomen van allergische rhinitis.

オランダ - オランダ語 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

cp-pharma handelsgesellschaft mbh - meloxicam - oplossing voor injectie - meloxicam 5 mg/ml, - meloxicam - honden; katten; runderen; varkens

オランダ - オランダ語 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

huvepharma nv - tylosine - premix voor gemedicineerd voer - tylosine 100 mg/g, - tylosin - fok- en vermeerderingskippen; slachtpluimvee; varkens